-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Holds Handover Ceremony for Mobility Vehicles Allocated to the Fourth Batch of High-Level Innovative Talents
Category:
发布时间：2023-07-12
【概要描述】
The refreshing coolness brought by a summer rain left both body and mind feeling exceptionally invigorated. The handover ceremony for mobility aids intended for high-level innovative talent at the Group’s R&D Center was presided over by Sun Lijie, Executive President of the Group and General Manager of the R&D Center. Shi Jianhui, Secretary of the Party Committee and Executive President of the Group, Tian Pengmei, Executive President of the Group and General Manager of the Strategic Development and Human Resources Center, and other leaders attended the ceremony and presented the mobility aids to the “stars” of the event—Ph.D. candidates and core research personnel from prestigious institutions such as Shanghai Jiao Tong University, Ocean University of China, Beijing Normal University, Jilin University, and Hebei Medical University.
“As a research and development professional at Shijiazhuang Sihua Pharmaceutical, I feel truly fortunate. I am deeply grateful for the Group’s care and support, and I will redouble my efforts to deliver outstanding results in return.” On the morning of July 12, Dr. Li Yuan expressed her delight after receiving the keys to her company-provided transportation vehicle at the handover ceremony for the fourth batch of high-level innovative talent mobility aids at the company’s R&D Center.
The refreshing coolness brought by a summer rain left both body and mind feeling exceptionally invigorated. The handover ceremony for mobility aids intended for high-level innovative talent at the Group’s R&D Center was presided over by Sun Lijie, Executive President of the Group and General Manager of the R&D Center. Shi Jianhui, Secretary of the Party Committee and Executive President of the Group, Tian Pengmei, Executive President of the Group and General Manager of the Strategic Development and Human Resources Center, and other leaders attended the ceremony and presented the mobility aids to the “stars” of the event—doctoral students and core research personnel from prestigious institutions such as Shanghai Jiao Tong University, Ocean University of China, Beijing Normal University, Jilin University, and Hebei Medical University.
According to available information, since 2021, Shijiazhuang Sihua Pharmaceutical Group has provided mobility vehicles to four batches of high-level talents and core research personnel.
“The only path to innovation lies in attracting and cultivating talent.” In recent years, Shijiazhuang Sihua Pharmaceutical Group has placed great emphasis on talent development, working vigorously to foster an environment that recognizes, values, respects, and effectively utilizes talent. The company regards its R&D personnel as highly sought-after assets; in addition to providing a world-class research infrastructure and competitive compensation and benefits, it also offers thoughtful support in areas such as transportation allowances and the provision of employee apartments, ensuring that its talented workforce can perform their duties with ease, comfort, and peace of mind. Through these efforts, the company continuously inspires its researchers to devote themselves wholeheartedly to scientific research and product development.
“We will undoubtedly cherish the work platform our company has created for us and the generous benefits it provides, firmly rooting ourselves in the front lines of innovation, weathering challenges, honing our capabilities, tempering our resolve, and leveraging our hard work and wisdom to deliver research outcomes that live up to the expectations of both our company and the times,” said Li Yuan.
Talent services and incentive measures have effectively propelled the high-quality development of corporate R&D and innovation. In recent years, Shijiazhuang Sihua Pharmaceutical has leveraged high-end R&D and innovation platforms—such as the nationally recognized Enterprise Technology Center and the National–Local Joint Engineering Laboratory—to align innovation initiatives with the industrial value chain, deepen the integration of industry and education as well as science and education, and capitalize on agglomeration advantages in technology, talent, and capital. The company has established research collaborations with institutions including China Pharmaceutical University, Zhengzhou University, Shenyang Pharmaceutical University, the Chinese Academy of Medical Sciences, and Hebei Medical University on complex formulations and innovative drugs, thereby addressing critical bottlenecks, accelerating the R&D and commercialization of specialty generic drugs, active pharmaceutical ingredients, innovative medicines, pharmaceutical packaging materials, and products undergoing bioequivalence evaluation, and achieving synchronized development across the entire drug R&D–market translation value chain. This has resulted in a uniquely structured product portfolio and new competitive advantages within the industry, continuously enhancing the company’s R&D innovation capabilities and efficiency, and steadily strengthening its innovation outcomes and core competitiveness. Currently, the Group’s accumulated innovations are yielding significant results, with an increasingly diversified product pipeline; in 2022, the Group secured approval for 37 new products. In the first half of this year, the Group ranked first nationwide among its peers in terms of the number of applications submitted, the number of products passing review, and the number of approvals granted, maintaining a leading position in R&D efficiency across the industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091